Alkermes PLC (NASDAQ:ALKS) CMO Elliot Ehrich sold 5,000 shares of Alkermes PLC stock in a transaction on Friday, September 16th. The shares were sold at an average price of $48.87, for a total value of $244,350.00. Following the completion of the transaction, the chief marketing officer now owns 50,311 shares in the company, valued at $2,458,698.57. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Elliot Ehrich also recently made the following trade(s):

  • On Tuesday, September 6th, Elliot Ehrich sold 10,000 shares of Alkermes PLC stock. The stock was sold at an average price of $46.02, for a total value of $460,200.00.
  • On Wednesday, July 27th, Elliot Ehrich sold 35,199 shares of Alkermes PLC stock. The stock was sold at an average price of $51.95, for a total value of $1,828,588.05.

Alkermes PLC (NASDAQ:ALKS) opened at 50.48 on Thursday. Alkermes PLC has a 1-year low of $27.14 and a 1-year high of $80.71. The stock’s market cap is $7.65 billion. The firm’s 50 day moving average price is $46.72 and its 200-day moving average price is $42.53.

Alkermes PLC (NASDAQ:ALKS) last posted its quarterly earnings data on Thursday, July 28th. The company reported ($0.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.09. Alkermes PLC had a negative return on equity of 14.18% and a negative net margin of 41.19%. The business had revenue of $195.20 million for the quarter, compared to analyst estimates of $174.15 million. During the same quarter in the prior year, the company earned ($0.09) earnings per share. The company’s revenue was up 28.9% on a year-over-year basis. On average, equities analysts anticipate that Alkermes PLC will post ($0.15) earnings per share for the current year.

ALKS has been the subject of a number of recent analyst reports. Barclays PLC reissued a “buy” rating and issued a $65.00 price objective (up previously from $50.00) on shares of Alkermes PLC in a research report on Tuesday, July 12th. Leerink Swann reissued an “outperform” rating and issued a $54.00 price objective (down previously from $58.00) on shares of Alkermes PLC in a research report on Tuesday, June 28th. JPMorgan Chase & Co. reissued a “hold” rating and issued a $51.00 price objective on shares of Alkermes PLC in a research report on Friday, July 29th. Evercore ISI initiated coverage on Alkermes PLC in a research report on Thursday, May 26th. They issued a “buy” rating and a $59.00 price objective for the company. Finally, Zacks Investment Research raised Alkermes PLC from a “hold” rating to a “buy” rating and set a $55.00 price objective for the company in a research report on Friday, August 5th. One research analyst has rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $53.90.

Institutional investors have recently bought and sold shares of the stock. Mn Services Vermogensbeheer B.V. raised its position in Alkermes PLC by 3.4% in the second quarter. Mn Services Vermogensbeheer B.V. now owns 3,829 shares of the company’s stock valued at $149,000 after buying an additional 127 shares during the period. Evercore Wealth Management LLC raised its position in Alkermes PLC by 1.2% in the second quarter. Evercore Wealth Management LLC now owns 14,366 shares of the company’s stock valued at $621,000 after buying an additional 166 shares during the period. IBM Retirement Fund raised its position in Alkermes PLC by 1.2% in the second quarter. IBM Retirement Fund now owns 15,193 shares of the company’s stock valued at $657,000 after buying an additional 177 shares during the period. Sumitomo Mitsui Asset Management Company LTD raised its position in Alkermes PLC by 2.1% in the second quarter. Sumitomo Mitsui Asset Management Company LTD now owns 9,651 shares of the company’s stock valued at $417,000 after buying an additional 196 shares during the period. Finally, Capstone Asset Management Co. raised its position in Alkermes PLC by 5.5% in the second quarter. Capstone Asset Management Co. now owns 6,285 shares of the company’s stock valued at $272,000 after buying an additional 330 shares during the period. 95.13% of the stock is currently owned by hedge funds and other institutional investors.

Alkermes PLC Company Profile

Alkermes Public Limited Company is a biopharmaceutical company. The Company is engaged in researching, developing and commercializing, both with partners and on its own, pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of approximately 20 products and a clinical pipeline of product candidates that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis.

5 Day Chart for NASDAQ:ALKS

Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.